The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Safety and efficacy of modified dose-attenuated FOLFIRINOX chemotherapy in patients over 65 years with advanced pancreatic adenocarcinoma.
Matheus Bongers Alessandretti
No relevant relationships to disclose
Erika Pereira Brandao
No relevant relationships to disclose
Carina Meira Abrahão
No relevant relationships to disclose
Aline Rocha Lino
No relevant relationships to disclose
Rodnei Macambira Junior
No relevant relationships to disclose
Marcos André Costa
No relevant relationships to disclose
Marcelo Rocha Cruz
No relevant relationships to disclose